These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 23050291)
21. [Shift of focus in the financing of Hungarian drugs. Reimbursement for orphan drugs for treating rare diseases: financing of enzyme replacement therapy in Hungary]. Szegedi M; Molnár MJ; Boncz I; Kosztolányi G Orv Hetil; 2014 Nov; 155(44):1735-41. PubMed ID: 25344850 [TBL] [Abstract][Full Text] [Related]
22. The European rare diseases therapeutic initiative. Fischer A; Borensztein P; Roussel C PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832 [TBL] [Abstract][Full Text] [Related]
23. EU to review rare disease drugs market exclusivity. Sheridan C Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455 [No Abstract] [Full Text] [Related]
24. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Douglas CM; Wilcox E; Burgess M; Lynd LD Health Policy; 2015 May; 119(5):588-96. PubMed ID: 25641123 [TBL] [Abstract][Full Text] [Related]
25. The balancing act of orphan drug pricing. The Lancet Lancet; 2017 Dec; 390(10113):2606. PubMed ID: 29256396 [No Abstract] [Full Text] [Related]
26. Personal reflections of a patient representative in an appraisal committee. Smit C Patient; 2015 Feb; 8(1):5-10. PubMed ID: 25256116 [No Abstract] [Full Text] [Related]
27. [Towards more targeted therapies in a contraint economy]. Toumi M Med Sci (Paris); 2018 May; 34 Hors série n°1():45-47. PubMed ID: 29911562 [No Abstract] [Full Text] [Related]
29. FDA program could boost treatments for neglected diseases. Traynor K Am J Health Syst Pharm; 2008 Sep; 65(17):1595-6. PubMed ID: 18714098 [No Abstract] [Full Text] [Related]
30. Rare Diseases: Addressing the Challenges in Diagnosis, Drug Approval, and Patient Access. Copley-Merriman K Value Health; 2018 May; 21(5):491-492. PubMed ID: 29753343 [No Abstract] [Full Text] [Related]
31. Rare disease resources not as rare as one might think. Burnworth MT Am J Health Syst Pharm; 2013 Jun; 70(12):1013-4. PubMed ID: 23719873 [No Abstract] [Full Text] [Related]
32. Duel over discounts. Pharma, providers at odds over 'orphan drugs'. Daly R Mod Healthc; 2012 Jan; 42(4):30-1. PubMed ID: 22359763 [No Abstract] [Full Text] [Related]
33. We need a "made in Canada" orphan drug framework. McMillan HJ; Campbell C CMAJ; 2017 Oct; 189(41):E1274-E1275. PubMed ID: 29038319 [No Abstract] [Full Text] [Related]
34. Rare diseases: the bane of modern society and the quest for cures. Azie N; Vincent J Clin Pharmacol Ther; 2012 Aug; 92(2):135-9. PubMed ID: 22814654 [TBL] [Abstract][Full Text] [Related]
36. Limits on use of health economic assessments for rare diseases. Hyry HI; Stern AD; Cox TM; Roos JC QJM; 2014 Mar; 107(3):241-5. PubMed ID: 24453281 [TBL] [Abstract][Full Text] [Related]
37. Regulators adopt more orphan drugs. Reardon S Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293 [No Abstract] [Full Text] [Related]
38. [Authorization and reimbursement of orphan drugs in an international comparison]. Roll K; Stargardt T; Schreyögg J Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380 [TBL] [Abstract][Full Text] [Related]
40. Law and research could add up to profitable niche drugs. Haefner B Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]